Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01987986 · ClinicalTrials.gov registry record · Phase 2
A Phase 2, Randomized, Double-blind, Placebo Controlled Dose Ranging Study of Repeat Doses of AA4500 for the Treatment of Edematous Fibrosclerotic Panniculopathy
A Phase 2 study of Edematous Fibrosclerotic Panniculopathy (EFP), sponsored by Endo Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 150
- Enrollment target
- 10
- Study locations
NCT01987986 is a Phase 2 study of Edematous Fibrosclerotic Panniculopathy (EFP) that has completed, run by Endo Pharmaceuticals. The registered enrollment target is 150 participants. The trial reports 10 study locations across 7 states.
The verdict
NCT01987986, a Phase 2 study of Edematous Fibrosclerotic Panniculopathy (EFP), has completed, sponsored by Endo Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 150 participants
- Enrollment target
- 10
- Study locations
Study Summary
To assess the safety and effectiveness of repeat doses of AA4500 in the treatment of edematous fibrosclerotic panniculopathy (EFP) commonly known as cellulite in adult women.
Conditions Studied
Interventions
- BIOLOGICAL Placebo
- BIOLOGICAL Collagenase Clostridium Histolyticum
Study Locations (10)
California
- Dermatology Cosmetic Laser Medical Associates of La Jolla - San Diego
- ATS Clinical Research - Santa Monica
Florida
- Dermatology Research Institute - Coral Gables
- Kenneth Beer, MD PA - West Palm Beach
New York
- Sadick Research Group - New York
- Stony Brook University Medical Center - Stony Brook
Missouri
- Mercy Health Research - Washington
Tennessee
- Tennessee Clinical Research Center - Nashville
Virginia
- Charlottesville Dermatology - Charlottesville
Washington
- Premier Clinical Research - Spokane
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 150 participants |
| Start Date | 2013-10 |
| Est. Completion | 2014-08 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01987986
The ClinicalTrials.gov registry entry for NCT01987986 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 150 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Endo Pharmaceuticals, which has 23 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Edematous Fibrosclerotic Panniculopathy (EFP) appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT01987986 reports 10 study locations spanning 7 distinct geographic areas - top geographies include California, Florida, New York.
Frequently Asked Questions
What is clinical trial NCT01987986 about?
NCT01987986 is a clinical study titled "A Phase 2, Randomized, Double-blind, Placebo Controlled Dose Ranging Study of Repeat Doses of AA4500 for the Treatment of Edematous Fibrosclerotic Panniculopathy". To assess the safety and effectiveness of repeat doses of AA4500 in the treatment of edematous fibrosclerotic panniculopathy (EFP) commonly known as cellulite in adult women.
What is the current status of trial NCT01987986?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 150 participants. The study started on 2013-10. Estimated completion is 2014-08.
What conditions does trial NCT01987986 study?
This clinical trial studies the following conditions: Edematous Fibrosclerotic Panniculopathy (EFP).
What interventions are being tested in trial NCT01987986?
The interventions under investigation include: Placebo (BIOLOGICAL), Collagenase Clostridium Histolyticum (BIOLOGICAL).
Who is sponsoring clinical trial NCT01987986?
This trial is sponsored by Endo Pharmaceuticals, which has 23 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01987986 being conducted?
This trial has 10 study locations across California, Florida, Missouri, New York, Tennessee. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.